Skip to main content

Table 5 Incidence of significant (i.e. grade 3, 4, or 5) bevacizumab-related adverse events

From: Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis

 

n = 2191

n = 973

n = 1218

 
 

Total

XELOX

FOLFOX

p-value

Hypertension

28 (1.3%)

15 (1.5%)

13 (1.1%)

0.344

Bleeding

10 (0.5%)

1 (0.1%)

9 (0.7%)

0.050

Gastrointestinal perforation

3 (0.1%)

0 (0.0%)

3 (0.2%)

0.259

Arterial thromboembolic event

8 (0.4%)

4 (0.4%)

4 (0.3%)

0.739

Venous thromboembolic event

17 (0.8%)

11 (1.1%)

6 (0.5%)

0.139

Proteinuria

5 (0.2%)

2 (0.2%)

3 (0.2%)

1.000